OptimizeRx Reaffirms 2023 Guidance

OptimizeRx Corporation (NASDAQ:OPRX) reaffirmed its 2023 over 10% revenue growth outlook, provided a positive update concerning the visibility it now has into achieving that target, and also introduced longer-term goals of reaching $100-120 million revenue and 20% EBITDA margin within the next 18-24 months.

Underpinning its confidence in the latter, management cites strong macro tailwinds, expanded offerings and strengthening commercial momentum.

Analysts at RBC Capital find all these encouraging but also noted growth thus far has been choppy, and absent M&A, achieving even the low end of the long-term revenue target would require a meaningful multi-year acceleration from 2022 and 2023 levels.